Información de la revista
Vol. 26. Núm. 5.
Páginas 303-306 (enero 2003)
Vol. 26. Núm. 5.
Páginas 303-306 (enero 2003)
Acceso a texto completo
Tratamiento antiviral en la cirrosis hepática por el virus de la hepatitis C
Visitas
4662
Servicio de Hepatología. Institut de Malalties Digestives. Hospital Clínic. Barcelona. España
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Y. Shiratori, O. Yokosuka, R. Nakata, M. Ihori, K. Hirota, M. Omata.
Prospective Study of Interferon Therapy for Compensated Cirrothic Patients With Chronic Hepatitis C by Monitoring Serum Hepatitis RNA.
Hepatology, 29 (1999), pp. 1573-1580
[2.]
S.W. Schalm, O. Weiland, B.E. Hansen, M. Milella, M.Y. Lai, J.T. Brouwer.
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials.
Gastroenterology, 117 (1999), pp. 408-431
[3.]
E.J. Heathcote, M.L. Schiffman, G.E. Cooksley, G.M. Dusheiko, S.S. Lee, J. Hofman.
Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med, 343 (2000), pp. 1673-1680
[4.]
M.P. Manns, J.G. Mc Hutchinson, S.C. Gordon, U.K. Rustyl, Shiffman, J.K. Albrecht.
Peginterferon alpha-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 358 (2001), pp. 958-965
[5.]
M.W. Fried, M.L. Shiffman, K. Rajender Reddy, C. Smith, G. Marinos, F.L. Gonçales, et al.
Peginterferon alpha-2a plus rivabirin for chronic hepatitis C virus infection.
N Engl J Med, 347 (2002), pp. 975-982
[6.]
T. Poynard, J. McHutchinson, G.L. Davis, R. Esteban Mur, Z. Goodman, P. Bedosa, et al.
Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
Hepatology, 32 (2000), pp. 1131-1137
[7.]
T. Poynard, J. McHutchinson, M. Manns, C. Trepo, K. Lindsay, Z. Goodman, et al.
Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
Gastroenterology, 122 (2002), pp. 1303-1313
[8.]
HALT-C Trial..
Hepatology, 36 (2002), pp. 792-793
[9.]
A. Halprin, J.F. Trotter, G. Everson, M. Wachs, T. Bak, M. Kugelmas, et al.
Post-transplant eradication of hepatitis C by pre-transplant treatment in living donor livin transplant recipients [abstract].
Hepatology, 34 (2001), pp. 244A
[10.]
S. Agrawal, S. Mehta, J. Daly, H.L. Bonkovsky, E. Katz, M. Halvorsen, et al.
Treatment of chronic hepatitis C with interferon alpha-2b and rivabirin in decompensated cirrhotics listed for transplant [abstract]. A retrospective study.
Hepatology, 34 (2001), pp. 322A
[11.]
J.S. Crippin, T. McCashland, N. Terrault, P. Sheiner, M.R. Charlton.
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
Liver Transplant, 8 (2002), pp. 350-355
[12.]
M. García-Retortillo, X. Forns, T. Serrano, F. Suárez, J.C. García-Valdecasas, M. Navasa, et al.
Efficacy and safety of combines treatment with interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Annual Meeting of the AASL.
Boston, (2002),
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados